TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00767572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
Study: NCT00583310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based lifestyle counseling
Description: Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
Study: NCT01655316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study: NCT04037124

Intervention type: PROCEDURE
Intervention: Cervical procedure
Description: simple hysterectomy, radical hysterectomy or fertility sparing surgery
Study: NCT01831895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD™
Description: Implant that is placed in the carotid sinus to control hypertension.
Study: NCT02779140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1632
Description: Monoclonal antibody mixture of XB10, XB18, and XB23

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1632
Description: Monoclonal antibody mixture of XB10, XB18, and XB23

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTM-1632
Description: Monoclonal antibody mixture of XB10, XB18, and XB23

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04645563

Intervention type: OTHER
Intervention: Sending thorax ct video images via smartphone applications
Description: Video images of the patients will be sent via smartphone application to infectious disease specialist for consulting.
Study: NCT04892732

Intervention type: DRUG
Intervention: Budesonide
Description: Budesonide dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: Budesonide-Formoterol
Description: Budesonide-Formoterol dispensing claim is used as the exposure group.
Study: NCT04426097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Vagal Blockade
Description: Cervical Vagal Blockade with 0.5 % ropivacaine 2.5 ml and 2% xylocaine 2.5 ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Without Blockade
Description: Without Blockade
Study: NCT01283100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg once every 24 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg once every 24 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg once every 24 hours for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200 mg once every 24 hours for 7 days
Study: NCT04083560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Vitamin B12 250mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Vitamin B12 250mcg
Study: NCT00847600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: 50 mg, caps.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: caps
Study: NCT00295165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Sargramostim 6 mcg/kg subcutaneously once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously once daily
Study: NCT01807533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program
Description: This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care intervention program
Description: This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
Study: NCT00349362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- 200mg intramuscular testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Saline intramuscular injection every two weeks
Study: NCT01456572

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ensure plus
Description: 17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standardized test meal
Description: scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standardized test meal
Description: scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
Study: NCT01413087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BC-819
Description: Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: BC-819
Description: Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)
Study: NCT05637359

Intervention type: DEVICE
Intervention: Tracked ultrasound measurement
Description: Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself.
Study: NCT04613544

Intervention type: DEVICE
Intervention: Voice Assist Arrhythmia Monitoring (VAAM)
Description: application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
Study: NCT01696903

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticojejunostomy technique
Description: The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
Study: NCT00636805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron (Aloxi) and Dexamethasone
Description: single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
Study: NCT02296736

Intervention type: RADIATION
Intervention: Computerised tomography (CT) scan
Description: Retrospective review of CT scans
Study: NCT03609892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
Study: NCT00542542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: Paravertebral block given as a bolus injection into the paravertebral space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-2.5 mg/kg IV over 1-4 hours during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50-250 mcg IV over 1-4 hours during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine given by injection into the paravertebral space along the spinal canal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.08 mg/kg IV over 1-4 hours during the surgery.
Study: NCT02169544

Intervention type: DRUG
Intervention: Abatacept
Study: NCT01743391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office-hysteroscopy with biopsy
Study: NCT00538317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirofiban
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
Study: NCT04061460

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mechanical plaque control
Description: supra and sub gingival debridment ( plaque control)
Study: NCT02038556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviorial therapy -Insomnia
Study: NCT04061460

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mechanical plaque control
Description: supra and sub gingival debridment ( plaque control)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mechanical plaque control
Description: supra and sub gingival debridment ( plaque control)
Study: NCT00566605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating keratoplasty with IntraLase
Description: penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty \[IEK\])

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating keratoplasty with vacuum trephine
Description: Group 2 - penetrating keratoplasty with vacuum trephine
Study: NCT04425070

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ICE [ifosfamide+carboplatin+etoposide]
Description: • Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).
Study: NCT01297153

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular Lens (Acrysof IOL)
Description: IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No IOL
Description: No IOL will be implanted in these eyes
Study: NCT04425070

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GEMOX [gemcitabine+oxaliplatin]
Description: • Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
Study: NCT00944710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Weekend atropine 1%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plano lens
Description: plano lens over the sound eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Weekend atropine 1%
Study: NCT00766324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: 6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: 24-hr IV infusion every 2 weeks in a 4-week cycle
Study: NCT01939314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
Study: NCT03728062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Guided mindfulness meditation focused on breath sensations, thoughts and emotions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
Study: NCT00735007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif® New Formulation (RNF) using RebiSmartTM
Description: RNF 44 mg, 3 times a week by subcutaneous injection.
Study: NCT04054544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten powder 4g
Description: Gluten powder 4g oral BID
Study: NCT00830765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (OHP17)
Description: 100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
Study: NCT03508778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof IQ PanOptix Trifocal IOL
Description: Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery per investigator's standard practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery per investigator's standard practice
Study: NCT03854942

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo oral tablet daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo oral tablet daily

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo oral tablet daily

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
Study: NCT01241422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 40929837
Description: On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
Study: NCT00969228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix ™
Description: Two oral doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two oral doses
Study: NCT02563899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium
Description: Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.